Dublin, Ireland, 25 May 2012 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its participation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual Meeting, taking place from June 2-6 in Washington, DC.
ICON, Oxford Outcomes and PriceSpective experts will speak at 22 educational and poster sessions on a range of topics, including observational research, advanced decision modelling on health economic evaluations, approaches for value based pricing, biosimilars and early stage economic models to integrate clinical and commercial development. Also at the event, Dr. Mark Sculpher, Senior Scientific Consultant, Health Economics at Oxford Outcomes, will address the meeting as President of ISPOR.
ICON acquired Oxford Outcomes in January 2011 to expand its Late Phase and Outcomes Research capabilities. In January 2012, ICON strengthened its expertise in value based pricing and market access through the acquisition of PriceSpective. Together with Oxford Outcomes and PriceSpective, ICON now offers a broad suite of integrated services to support early-stage, pre-launch and post-launch decision making.
Attendees will be able to meet ICON’s senior executives by visiting the ICON booth (#87-90) in the exhibit hall.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 8,500 employees, operating from 84 locations in 40 countries.
Further information is available at www.iconplc.com
ICON Media Contact:
+44 (0)20 7067 0594